12:27 PM EST - Novamind Inc : Announced it is enrolling participants in a phase II clinical trial sponsored by Alto Neuroscience, a clinical stage company focused on pioneering the field of precision psychiatry. The eight-week clinical trial currently underway at Novamind's Draper, Utah research site is investigating an antidepressant medication for adults with major depressive disorder and post-traumatic stress disorder. Novamind Inc
shares C.NM are trading unchanged at $0.30.
